

### AMENDMENTS TO THE CLAIMS

A complete set of claims is included below, as well as the current status of each claim. This listing of claims replaces all prior versions, and listings, of claims in the application.

20. (Previously presented) The cell culture ~~SC-02MFP~~ SC-01MFP deposited as Accession Number FERM BP-10077 ~~FERM BP-10078~~.

21. (Previously presented) The cell culture ~~SC-01MFP~~ SC-02MFP deposited as Accession Number FERM BP-10078 ~~FERM BP-10077~~.

22. (New) A human myeloma cell strain, for the continuous production of a desired protein from an exogenous gene at a yield of 1 ng – 10 µg/day per 1,000,000 cells at least over a 2-month period,

wherein said human myeloma cell strain is established by

a) selecting a human myeloma cell strain with a total intracellular protein in the range of about 0.1 – 1.0 mg per 1,000,000 cell; and

b) choosing cell clones of said human myeloma cell strain which have a doubling time of 18 to 24 hours and a 90% rate of cloning by limiting dilution method, adding a carcinogen to said cell clones, and selecting, those cells which have a doubling time of 18 to 24 hours and a 90% rate of cloning by limiting dilution method;

said human myeloma cell strain being further characterized in that after a gene encoding a desired protein is transfected into it, the transfected cell is subsequently cultured in a serum free medium.

23. (New) A human myeloma cell strain, for the continuous production of a desired protein from an exogenous gene at a yield of 1 ng – 10 µg/day per 1,000,000 cells at least over a 2-month period,

wherein said human myeloma cell strain is established by

a) selecting a human myeloma cell strain with a total intracellular protein in the range of about 0.1 – 1.0 mg per 1,000,000 cell; and

b) choosing cell clones of said human myeloma cell strain which have a doubling time of 18 to 24 hours and a 90% rate of cloning by limiting dilution method, adding a carcinogen to said cell clones, and selecting, those cells which have a doubling time of 18 to 24 hours and a 90% rate of cloning by limiting dilution method, to be said human myeloma cell strain,

said human myeloma cell strain being further characterized in that the human myeloma cell strain is SC-01MFP (Accession No. FERM BP-10077) or SC-02MFP (Accession No. FERM BP-10078) and after a gene encoding a desired protein is transfected into it, the transfected cell is subsequently cultured in a serum free medium.

24. (New) A human myeloma cell strain, for the continuous production of a desired protein from an exogenous gene at a yield of 1 ng – 10 µg/day per 1,000,000 cells at least over a 2-month period,

wherein said human myeloma cell strain is SC-01MFP (Accession No. FERM BP-10077) or SC-02MFP (Accession No. FERM BP-10078).